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Caroline A SabinAbstract
There is evidence that the life expectancy (LE) of individuals infected with the human immunodeficiency virus (HIV)
has increased since the introduction of combination antiretroviral therapy (cART). However, mortality rates in recent
years in HIV-positive individuals appear to have remained higher than would be expected based on rates seen in
the general population. A low CD4 count, whether due to late HIV diagnosis, late initiation of cART, or incomplete
adherence to cART, remains the dominant predictor of LE, and thus the individual’s disease stage at initiation of
cART (or thereafter) certainly contributes to these higher mortality rates. However, individuals with HIV also tend to
exhibit lifestyles and behaviors that place them at increased risk of mortality, particularly from non-AIDS causes.
Thus, although mortality rates among the HIV population may indeed remain slightly higher than those seen in the
general population, they may be no higher than those seen in a more appropriately matched control group. Thus,
further improvements in LE may now only be possible if some of the other underlying issues (for example,
modification of lifestyle or behavioral factors) are tackled.
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Approximately 34.3 million people worldwide are thought
to be infected with the human immunodeficiency virus
(HIV) [1]. Left untreated, HIV is inevitably fatal, with a
median survival time from seroconversion of 8 to 10 years
[2]. However, the widespread introduction of combination
antiretroviral therapy (cART) in many countries in the
mid-1990s resulted in a rapid and dramatic reduction in
mortality in those living with HIV [3,4]. Although the
early cART regimens often included drugs with side ef-
fects that limited their efficacy, the drugs used as part
of modern cART combinations are generally easier to
take, have fewer side effects, and are more forgiving of
minor lapses in adherence. As a result, immunological
and virological responses to cART have continued to
improve over time, with resulting continued reductions
in mortality [5,6]. HIV has now come to be viewed by
many as a chronic disease and, for the first time, the HIV
research community has started to discuss the possibilityCorrespondence: c.sabin@ucl.ac.uk
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2013that life expectancy (LE) in those infected with HIV may
now be approaching that seen in the general population.
The aim of this review is to describe changes in LE in
the HIV-positive population since the introduction of
cART, and to consider whether this has now reached the
same level as in those without HIV infection.What is life expectancy?
LE is an important indicator of health that is used widely
by governments, healthcare agencies, and insurance com-
panies to monitor trends in survival over time, and to de-
termine resource allocation [7]. Formally, LE indicates the
average number of years that a person would be expected
to survive beyond a given age. That given age would usually
be birth [8]; however, in the context of HIV, the given age
may be difficult to interpret as, in most cases, individuals
are not born with HIV but acquire it at some point during
their life. Thus, LE is commonly quoted from a specific
given age [9-11] or after some specific event, such as
HIV diagnosis [12,13]. Of note, LE at a particular age is
not the same as LE at birth minus that age, as LE at ais is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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that the individual has already survived to that age.
To describe the effect of a particular infection, such
as HIV, on LE, investigators may prefer to report the
potential years of life lost due to that infection. These may
be ‘productive’ life years lost before the age of 65 years [9],
or may be overall years of life lost [14]. Alternatively,
investigators may report the potential gains in LE that
could be achieved if that infection (in this case, HIV)
were to be eliminated from the population [15-17], the
excess mortality rates due to HIV [18], or the standardized
mortality ratio (SMR) or mortality rate ratio [19,20], both
of which provide a relative measure of the mortality rate
in HIV-positive individuals compared with the expected
mortality rate in an age-matched uninfected population.
The variety of statistics that may be quoted, and the
different ages at which LE may be expressed, complicates
attempts to summarize LE in the cART era. Table 1
lists reported estimates of LE in the cART era from
resource-rich settings, which range from 19.9 years at
the age of 25 years in Denmark [21], to around 75 years
from birth in the UK [8].
Changes in LE in the cART era
It is clear that LE has increased since the introduction of
cART. Using data from the large CASCADE Collaboration,Table 1 Estimates of LE reported in the cART era
Reference Cohort/study name Country of study LE









(Europe and North America)
LE
35
Johnson et al. [10] IeDEA-SA South Africa LE
36
10











Bor et al. [17] KwaZulu-Natal, South Africa No










van Sighem et al. [41] ATHENA Cohort The Netherlands LE
57
Abbreviations: cART, combination antiretroviral therapy; LE, life expectancy.Bhaskaran [18] found a continued narrowing in the gap in
mortality rates between those seen in individuals infected
with HIV with known dates of HIV seroconversion and
those that would have been expected based on a demo-
graphically similar HIV-negative population. Excess mor-
tality rates in the HIV-positive population dropped by 94%
from 31.4 per 1000 person-years (PYRS) prior to 1996
to 6.1 per 1000 PYRS in 2004 to 2006. Mortality rates
among 43,355 cART-naive participants in the Antiretroviral
Therapy Cohort Collaboration (ART-CC) dropped similarly
from 16.3 per 1000 PYRS in 1996 to 1999, to 10.0 per 1000
PYRS in 2003 to 2005 [9]. LE at 20 and 35 years increased
from 36.1 and 25.0 years to 49.4 and 37.3 years, respect-
ively, over the same period, with the potential years of
life lost decreasing from 366 per 1000 PYRS to 189 per
1000 PYRS. Among participants with acquired immune
deficiency syndrome (AIDS) in the Longitudinal Study
of Ocular Complications in AIDS [22], excess mortality
decreased by 8.0% per year from the period 1999 to
2001 to the period 2006 to 2007. LE at age 25 years in
the Danish HIV cohort increased from only 8 years in
the pre-cART era (1995 to 1996) to 33 years in 2000 to
2005, with LE for a similarly aged uninfected Danish
person during that period being 51 years [21]. Among
individuals starting cART in the UK Collaborative HIV
Cohort (CHIC) Study, LE at 20 years increased fromin HIV-positive population LE in general population
at birth: 75.0 years if diagnosed with
V with high CD4 count; 71.5 years if
gnosed with HIV with low CD4 count
LE at birth: estimated from model
to be 82.0 years if not infected
with HIV
at age 20: 43.1 years. LE at age
: 31.7 years
Not stated
at age 20: 27.6 years in men;
.8 years in women. LE at age 60:
.1 years in men; 14.4 years in women
Not stated
at age 20: 26.7 years. LE at age
years: 27.9 years
LE at age 20: 41 years
at age 33: 22.66 years if optimally
gnosed and treated; 19.36 years if
ated with cART and adherence
llows normal patterns
LE at age 33: 42.91 years for
general population; 34.58 years if
risk profile similar to those with HIV
specific estimates LE at birth: 52.3 years in 2000; 49.2
years in 2003; 60.5 years in 2011
at age 25: 8 years in 1995 to 1996;
years in 1997 to 1999; 33 years in
00 to 2005
LE at age 25: 51 years
at age 20: 39.5 years in men;
.2 years in women. LE at age 35:
.1 years in men; 37.7 years in women
LE at age 20: 57.8 years in men;
61.6 years in women. LE at age 35:
43.5 years in men; 46.9 years
in women
at age 25: 52.7 years in men;
.8 years in women
LE at age 25: 53.1 years in men;
58.1 years in women
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45.8 years if cART was started during 2006 to 2008
[23]. Of note, improvements in LE in the cART era are not
restricted to resource-rich settings: the overall population
LE at birth in KwaZulu-Natal, South Africa, is reported to
have increased from 49.2 years in 2003 (prior to the scale-
up of antiretroviral therapy), to 60.5 years in 2011 [17].
Predictors of LE in the cART era: the role of disease stage
Despite the dramatic improvements in LE witnessed since
the introduction of cART, LE may still not have reached
the levels seen in the uninfected population. Bhaskaran [18]
reported that even by 2003 to 2005, excess mortality
rates in the CASCADE Collaboration remained elevated
at 6.1 per 1000 PYRS, and in the ART-CC, potential
years of life lost remained high (189 per 1000 PYRS)
over the period 2003 to 2005 [9]. LE in patients starting
cART in 2008 in the UK CHIC Study remained lower than
that seen in the UK general population (59 years at age 20)
[23]. Among women in the US Women’s Interagency
HIV Study (WIHS), the SMR dropped from 24.7 in
1996 to a plateau of 10.3 during 2001 to 2003, despite
the addition of a group of younger and healthier women
into the cohort in 2001 to 2002 [19].
The disease stage of individuals at the time of initiation
of cART, and shortly thereafter, may at least partly
contribute to the higher than expected mortality rates
seen in recent years (Table 2). In the Longitudinal Study
of Ocular Complications in AIDS [22], excess death rates
ranged from 128 per 1000 PYRS in individuals who had
cytomegalovirus retinitis, a viral load of greater than 400
copies/ml, and a CD4 count of less than 200 cells/mm3,
to only 8 per 1000 PYRS for individuals lacking these
factors. Interestingly, although excess mortality rates in
this study dropped in the cART era by 8.3% per year in
those with a CD4 count of less that 200 cells/mm3, no sig-
nificant reduction was seen in those with higher CD4 cell
counts. In ART-CC participants [24], the lowest SMR was
seen in men who have sex with men (MSM), who did not
have AIDS at cART initiation and who had attained a viral
load of 500 copies/ml or lower and a CD4 cell count of
350 cells/mm3 or higher by 6 months after starting cART.
By contrast, the highest SMR was seen in injection drugTable 2 Summary of factors that may influence LE in people
Sociodemographic factors Lifestyle/behavioral fa
Gender Smoking
Age Alcohol use
Co-morbidities related to aging Recreational and injectio
Ethnic group/country of origin Viral hepatitis co-infectio
Place of residence/neighborhood Sexually transmitted infe
Socioeconomic status
Abbreviations: cART, combination antiretroviral therapy; LE, life expectancy.users who failed to attain a suppressed viral load by
6 months and in whom the CD4 cell count remained at
less than 50 cells/mm3.
The important association between the pre-cART CD4
count and LE has been described in several other studies.
In the UK CHIC Study [23], individuals started on cART
in line with UK guidelines (at a CD4 cell count of 200 to
350 cells/mm3) experienced a LE at age 20 of 53.4 years,
only marginally shorter than that seen in the general male
(57.8 years) and female (61.6 years) populations. By
contrast, LEs at age 20 were only 41.0 and 37.9 years
among those started on cART at a CD4 count of 100 to
199 and less than 100 cells/mm3, respectively. Among
cART-treated South African individuals, LE at age 20
ranged from 43.1 years if the CD4 count was 200 cells/mm3
or higher to 29.5 years if the CD4 count was 50 cells/mm3
or lower [10]. In Australian cART-treated individuals [25],
the SMR increased from 1.5 among individuals with a CD4
count of 500 cells/mm3 or higher to 8.6 among those with a
CD4 cell count of 350 cells/mm3 or lower. Finally, among
HIV-positive individuals in the Study of Fat Redistribution
and Metabolic change in HIV Infection (FRAM), mor-
tality rates were 2.3 times higher than in HIV-negative
controls in individuals with a CD4 count of greater
than 350 cells/mm3, but 6.3 times higher in those with
a CD4 count of less than 350 cells/mm3 [26]. Thus, it is
clear that a low CD4 count, whether due to late diagnosis
of HIV, late initiation of cART, or incomplete adherence
to cART, remains the dominant predictor of LE in the
cART era.
Predictors of LE in the cART era: the role of non-HIV factors
Although stage of HIV disease at cART initiation is
strongly associated with LE, other factors may also play
a role. (Table 2) Individuals with HIV are known to exhibit
lifestyles and behaviors that put them at higher risk of
mortality than the general population, regardless of
HIV status, including higher rates of smoking, alcohol
and recreational drug use, and viral and sexually trans-
mitted co-infections [27-30]. Current smoking was an
additional risk factor for death in HIV-positive individ-
uals in the FRAM Study [26], and in a recent study from
the Danish HIV Cohort, Helleberg et al. [31] reportedwith HIV infection
ctors HIV-related factors
Late HIV diagnosis
CD4 count at cART initiation
n drug use CD4 count and HIV RNA attained on cART
n Clinical AIDS prior to cART initiation
ctions Attendance at outpatient clinics
Adherence to cART
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smoking than to HIV itself. Among participants in the
ART-CC [9], injection drug users had a LE that was
around 13 years shorter at age 20, and 10 years shorter
at age 35, than non-injection drug users. The percent-
age of participants in this study with a SMR less than 2
(that is, individuals whose mortality patterns most closely
resembled those in the general population) was 46% in
MSM, 42% in those infected with HIV through heterosex-
ual sex, and 0% among injection drug users; the corre-
sponding percentages of participants with a SMR greater
than 10 (individuals with the worst mortality patterns)
were 4%, 14%, and 47%,s respectively [24], confirming
the negative impact of injection drug use and/or hepatitis
co-infection on overall mortality rates [19,21].
Although these non-HIV factors may have only a limited
influence on deaths from AIDS-related causes, they may
play a more major role in deaths from non-AIDS causes,
which appear to have increased in frequency in the cART
era. In the WIHS Study [19], deaths from non-AIDS causes
increased in the cART era, and by 2001 to 2004, they
accounted for the majority of deaths that occurred; it was
this increase in non-AIDS deaths that was thought to con-
tribute to the plateau in the SMR seen from 2001 among
women in the study. Whereas the mortality rate ratio for
deaths from non-AIDS causes in non-injection drug users
in the Danish HIV Cohort had dropped from 4.5 in 1995 to
1.3 in 2008, it had increased from 7.0 to 10.3 over the same
period in injection drug users [32]. In a direct comparison
with the Multicenter AIDS Cohort Study (MACS), Wada
[33] reported that median LE for non-AIDS causes was al-
most 10 years shorter in women in the WIHS (55.9 years)
than in men in the MACS (66.0 years), contributing to an
overall difference in age at death between men and women
of 11.6 years. Further evidence of the potential role of
non-HIV factors in mortality rates comes from Alabama
[34], where patients who missed visits in the first year
after initiating outpatient treatment for HIV had over
twice the rate of long-term mortality compared with
those attending all scheduled appointments, and from
Canada, where a three-fold increased risk of death was
seen in cART-treated HIV-positive individuals who lived
in neighborhoods with a high concentration of injection
drug users, relative to those who lived in neighborhoods
with a high concentration of MSM [35].
To investigate the potential effect of these external factors
on the mortality rates seen, Lohse [36] used data from the
Danish general population to show that only around
55% of deaths that occurred in the Danish HIV cohort
could be attributed to HIV, with 32% of deaths being
attributed to hepatitis C virus co-infection and/or other
co-morbidities, and the remaining 14% being unrelated
to either HIV or co-morbidities. Losina and colleagues
[12] used the CEPAC model, a state-transition modelof HIV infection, to quantify the potential influence on
LE of various lifestyle and behavioral factors. They
found that in the general US population, LE at age 33
(the mean age at seroconversion in the USA) was around
43 years [12], but this dropped to 34.58 years when the au-
thors selected a cohort from the HIV-negative population
that matched their HIV-positive population in terms of sev-
eral lifestyle and sexual risk factors. The authors were then
able to estimate that HIV infection, when appropriately
treated and diagnosed at an early stage, would lead to a fur-
ther loss of LE of around 11.92 years, with late diagnosis,
late initiation of cART, and early discontinuation of cART
further reducing LE by an additional 3.3 years [12].
Can we improve LE further?
Late HIV diagnosis remains extremely common in many
countries [37], and has been reported to be a major risk
factor for mortality [38]. In Brazil, it was estimated that
95.5% of deaths occurring in the first year after diagnosis
were attributable to late diagnosis [39]; study investiga-
tors estimated that averting late diagnosis would have
reduced the AIDS mortality rate 2003 to 2006 by 39.5%,
a similar reduction to that produced by cART. In the
UK, earlier diagnosis would have reduced short-term
(first year after diagnosis) mortality by 84% in MSM
[38] and by 56% in those infected heterosexually [40].
Using the HIV Synthesis model, a stochastic computer
simulation model of HIV progression, Nakagawa [8]
showed that LE from birth was 71.5 years, with 10.5 years
lost to HIV infection, in a scenario in which diagnosis oc-
curred at a late stage of HIV infection (median CD4 count
140 cells/mm3), but under a scenario of earlier diagnosis
(median CD4 count 432 cells/mm3), LE from birth was
75.0 years, with only 7.0 years lost, on average, due to
HIV. Thus, earlier diagnosis of HIV might go some way
to improve LE further.
Among those diagnosed and receiving cART, efforts to
ensure that all individuals attain optimal CD4 levels may
also lead to improvements in LE. Lewden calculated SMR
for individuals in the COHERE collaboration who had
attained a CD4 count of 500 cells/mm3 or higher on cART
[20]. For men, attaining a CD4 count of 500 cells/mm3 or
higher for just over 1 year was sufficient to ensure that
their mortality rates were similar to those in the general
population. For women, however, SMR remained above
1, even among those who had maintained a CD4 count
of 500 cells/mm3 or higher for over 5 years. The poten-
tial for further improvement in LE was also studied in
the Dutch ATHENA cohort [41]; LE at age 25 among
HIV-positive participants who had been diagnosed
during 1998 to 2007 and who remained AIDS-free and
untreated for 24 weeks after diagnosis was 52.7 years
in men (versus 53.1 years in the general population) and
57.8 years in women (versus 58.1 years). The authors noted
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(injection drug users were excluded) with a median CD4
count at 24 weeks after diagnosis of 480 cells/mm3, and
therefore the outcomes reported reflect the potential
outcomes that might be feasible in a group of patients
diagnosed and treated at an early stage of infection. Of
note, there is some evidence to suggest a small potential
benefit of cART (through a reduction in CD4 loss) if it
is initiated during primary HIV infection [42]. Although
such benefits may translate into further improvements
in LE, any effect at a population level is likely to be small,
given the difficulties in diagnosing individuals with HIV
infection at such an early stage.
Earlier HIV diagnosis and optimal cART initiation aside,
do we still have some way to go to improve LE, or have we
already reached the maximum LE that might be anticipated
in this population? Although LE in those with HIV infec-
tion is generally compared with that seen in the general
population in the same country, LEs vary tremendously
both between and within countries. In the UK, for ex-
ample, male LE at birth in 2007 to 2009 ranged from
84.4 years for those living in parts of London to 73.1 years
for those living in parts of Glasgow [43]. Even within a city
such as London, there may be large differences in LE in
different areas, as shown by the Lives on the Line project
(http://life.mappinglondon.co.uk/). These differences may
be explained by differences in the characteristics of those
living in different regions, particularly socioeconomic
status, lifestyle factors, and dietary factors. When LE is
compared between the HIV-positive and the general
populations, therefore, the two populations may have a
different underlying risk of mortality, and LEs may be
expected to differ from that in the general population.
The identification of appropriately matched HIV-negative
control populations, with similar lifestyle and behavioral
characteristics, for the provision of comparative estimates
of LE, would go some way to addressing this concern.
This inability to eliminate residual confounding is a
limitation of any comparison based on observational data.
However, LE also suffers from several other limitations.
Firstly, LE is generally based on current mortality rates
and does not take into consideration any improvements
to patient management that may occur in the future
(leading to an underestimate of future LE) nor to any
longer-term possible adverse outcomes of cART or HIV
infection (leading to an overestimate of future LE). Sec-
ondly, the estimation of LE often requires long-term ex-
trapolation of mortality rates from individuals followed
over a relatively short period. After all, HIV has only been
around for 30 years or so, a relatively short time compared
with the length of an individual’s lifetime. Finally, LE is
only as good as the ascertainment of deaths within a
cohort; where deaths are not fully ascertained, LE may
appear artificially high. Using information collected fromcohort studies in West Africa, Cote d’Ivoire, and Burkina
Faso, Lewden et al. [44] reported that the highest estimates
of mortality were seen in cohorts with the lowest rates of
loss to follow-up. Verguet et al. [45] subsequently reported
that whereas the best estimate of life years gained by a
person in Africa in the first 5 years after starting cART
was 2.1 [45], this estimate could drop by approximately
14% if mortality rates among those lost to follow-up
were assumed to be 100%, or could increase by 19% if zero
mortality was assumed in this group. In cohorts participat-
ing in the ART-CC, incomplete death ascertainment was
reported to contribute to the higher mortality rates seen
in the North American compared with European cohorts,
although other patient factors also played a role [46].
Conclusions
With the limitations described above in mind, it is possible
that LE may now have reached levels that we would expect
to see in this population. At this stage, it is possible that fur-
ther major improvements in LE may only be achievable by
tackling some of the other underlying issues, such as earlier
HIV diagnosis (through enhanced opportunities for testing
and greater awareness of the early signs of HIV infection)
and improved retention in HIV care, earlier cART initi-
ation, or the modification of lifestyle or behavioral factors.
Abbreviations
AIDS: Acquired immune deficiency syndrome; ART-CC: Antiretroviral therapy
cohort collaboration; cART: Combination antiretroviral therapy; HIV: Human
immunodeficiency virus; LE: Life expectancy; MACS: Multicenter AIDS cohort
study; MSM: Men who have sex with men; PYRS: Person-years;
SMR: Standardised mortality ratio; UK CHIC study: UK collaborative HIV cohort
study; US: United States; WIHS: Women’s interagency HIV study.
Competing interests
The author declares that she has no competing interests.
Author’s information
CS is a professor of Medical Statistics and Epidemiology at University College
London (UCL). She has worked for many years on the analysis of large
observational HIV databases, with a particular interest in raising awareness of
the biases inherent in these databases. She is the principal investigator on
the UK CHIC Study, principal statistician on the D:A:D Study, and has worked
with many other research groups in the UK and elsewhere.
Received: 10 October 2013 Accepted: 30 October 2013
Published:
References
1. Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDSInfo. http://www.
unaids.org/en/dataanalysis/datatools/aidsinfo/.
2. Porter K, Johnson AM, Phillips AN, Darbyshire JH: The practical significance
of potential biases in estimates of the AIDS incubation period distribution
in the UK Register of HIV Seroconverters. AIDS 1999, 13:1943–1951.
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d’Arminio Monforte A,
Knysz B, Dietrich M, Phillips AN, Lundgren JD: Decline in the AIDS and
death rates in the EuroSIDA study: an observational study. Lancet 2003,
362:22–29.
4. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA,
Aschman DJ, Holmberg SD: Declining morbidity and mortality among
patients with advanced human immunodeficiency virus infection. N Engl
J Med 1998, 338:853–860.
27 Nov 2013
Sabin BMC Medicine Page 6 of 72013, 11:251
http://www.biomedcentral.com/1741-7015/11/2515. Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T,
Easterbrook P, Gilson R, Johnson M, Porter K, Anderson J, Gompels M, Leen
C, Ainsworth J, Orkin C, Nelson M, Rice B, Phillips A: Trends over calendar
time in antiretroviral treatment success and failure in HIV clinic
populations. HIV Med 2010, 11:432–438.
6. Lampe FC, Smith CJ, Madge S, Kinloch-de Loes S, Tyrer M, Sabin CA, Chaloner C,
Youle M, Johnson MA, Phillips AN: Success of clinical care for human
immunodeficiency virus infection according to demographic group
among sexually infected patients in a routine clinic population,
1999 to 2004. Arch Int Med 2007, 167:692–700.
7. May MT, Ingle SM: Life expectancy of HIV-positive adults: a review.
Sex Health 2011, 8:526–533.
8. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD,
Delpech V, Phillips AN: Projected life expectancy of people with HIV
according to timing of diagnosis. AIDS 2012, 26:335–343.
9. The Antiretroviral Therapy Cohort Collaboration: Life expectancy of individuals
on combination antiretroviral therapy in high-income countries:
a collaborative analysis of 14 cohort studies. Lancet 2008, 372:293–299.
10. Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser
O, Fox MP, Wood R, Prozesky H, Giddy J, Belen Garone D, Cornell M, Egger
M, Boulle A: Life expectancies of South African adults starting
antiretroviral treatment: collaborative analysis of cohort studies.
PLoS Med 2013, 10:e1001418.
11. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, Nachega JB, Dybul
M, Hogg RS: Life expectancy of persons receiving antiretroviral therapy
in low-income countries: a cohort analysis from Uganda. Ann Int Med
2011, 155:209–216.
12. Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ,
Weinstein MC, Hicks PL, Aaronson WH, Moore RD, Paltiel AD, Freedberg KA:
Racial and sex disparities in life expectancy losses among HIV-infected
persons in the United States: impact of risk behaviour, late initiation,
and early discontinuation of antiretroviral therapy. Clin Infect Dis 2009,
49:1570–1578.
13. Fang CT, Chang YY, Hsu HM, Twu SJ, Chen KT, Lin CC, Huang LYL, Chen MY,
Hwang JS, Wang JK, Chuang DY: Life expectancy of patients with
newly-diagnosed HIV infection in the era of highly active antiretroviral
therapy. Q J Med 2007, 100:97–105.
14. Aragon TJ, Lichtensztajn DY, Katcher BS, Reiter R, Katz MH: Calculating
expected years of life lost for assessing local ethnic disparities in causes
of premature death. BMC Pub Health 2008, 8:116.
15. Wang GD, Lai DJ, Burau KD, Du XL: Potential gains in life expectancy
from reducing heart disease, cancer, Alzheimer’s disease, kidney
disease or HIV/AIDS as major causes of death in the USA. Pub Health
2013, 127:348–356.
16. Lai DJ, Tarwater PM, Hardy RJ: Measuring the impact of HIV/AIDS, heart
disease and malignant neoplasms on life expectancy in the USA from
1987 to 2000. Pub Health 2006, 120:486–492.
17. Bor J, Herbst AJ, Newell M-L, Barnighausen T: Increases in adult life
expectancy in rural South Africa: valuing the scale-up of HIV treatment.
Science 2013, 339:961–965.
18. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC,
Porter K: Changes in the risk of death after HIV seroconversion compared
with mortality in the general population. JAMA 2008, 300:51–59.
19. French AL, Sawel SH, Hershow R, Benning L, Hessol NA, Levine AM, Anastos
K, Augenbraun M, Cohen MH: Trends in mortality and causes of death
among women with HIV in the United States: a 10-year study.
J Acquir Imm Defic Syndr 2009, 51:399–406.
20. Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van
Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C,
Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d’Arminio
Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J,
Chene G: All-cause mortality in treated HIV-infected adults with
CD4 ≥500/mm3 compared with the general population: evidence from
a large European observational cohort collaboration. Int J Epidemiol
2012, 41:433–445.
21. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT,
Vaeth M, Obel N: Survival of persons with and without HIV infection in
Denmark, 1995–2005. Ann Intern Med 2007, 146:87–95.
22. Puhan MA, Van Natta ML, Palella FJ, Addessi A, Meinert C: Excess mortality
in patients with AIDS in the era of highly active antiretroviral therapy:
temporal changes and risk factors. Clin Infect Dis 2010, 51:947–956.23. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D,
Palfreeman A, Gilson R, Gazzard B, Hill T, Walsh J, Fisher M, Orkin C,
Ainsworth J, Bansi L, Phillips A, Leen C, Nelson M, Anderson J, Sabin C:
Impact of late diagnosis and treatment on life expectancy in people
with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. Brit Med J 2011,
343:d6016.
24. The Antiretroviral Therapy Cohort Collaboration: Mortality of HIV-infected
patients starting potent antiretroviral therapy: comparison with the
general population in nine industrialized countries. Int J Epidemiol 2009,
38:1624–1633.
25. McManus H, O’Connor CC, Boyd M, Broom J, Russell D, Watson K, Roth N,
Read PJ, Petoumenos K, Law MG: Long-term survival in HIV positive patients
with up to 15 years of antiretroviral therapy. PLoS ONE 2012, 7:e48839.
26. Cockerham L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P,
Grunfeld C, Shlipak M, Tien PC: Association of HIV infection, demographic
and cardiovascular risk factors with all-cause mortality in the recent
HAART era. J Acquir Imm Defic Syndr 2010, 53:102–106.
27. Galvan FH, Bing EG, Fleishman JA, London AS, Caetano R, Burnam MA,
Longshore D, Morton SC, Orlando M, Shapiro M: The prevalence of alcohol
consumption and heavy drinking among people with HIV in the United
States: results from the HIV Cost and Services Utilization Study.
J Study Alcohol 2002, 63:179–186.
28. Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d’Arminio Monforte A,
Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN,
Lundgren JD: Cardiovascular disease risk factors in HIV patients–association
with antiretroviral therapy. Results from the DAD study. AIDS 2003,
17:1179–1193.
29. Mimiaga MJ, Reisner SL, Grasso C, Crane HM, Safren SA, Kitahata MM,
Schumacher JE, Mathews WC, Mayer KH: Substance use among HIV-infected
patients engaged in primary care in the United States: findings from the
Centers for AIDS Research Network of Integrated Clinical Systems cohort.
Am J Pub Health 2013, 103:1457–1467.
30. Health Protection Agency: HIV in the United Kingdom: 2012 Report. London:
Health Protection Services, Colindale; 2012.
31. Helleberg M, Afzal S, Kronborg G, Larsen CS, Pedersen G, Pedersen C,
Gerstoft J, Nordestgaard BG, Obel N: Mortality attributable to smoking
among HIV-1-infected individuals: a nationwide, population-based
cohort study. Clin Infect Dis 2013, 56:727–734.
32. Helleberg M, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Gerstoft J,
Obel N: Causes of death among Danish HIV patients compared with
population controls in the period 1995–2008. Infection 2012, 40:627–637.
33. Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A: Cause-specific
life expectancies after 35 years of age for human immunodeficiency
syndrome-infected and human immunodeficiency syndrome-negative
individuals followed simultaneously in long-term cohort studies,
1984–2008. Am J Epidemiol 2013, 177:116–125.
34. Mugavero MJ, Lin H-Y, Willig JH, Westfall AO, Ulett KB, Routman JS, Abroms
S, Raper JL, Saag MS, Allison JJ: Missed visits and mortality among patients
establishing initial outpatient HIV treatment. Clin Infect Dis 2009, 48:248–256.
35. Druyts EF, Rachlis BS, Lima VD, Harvard SS, Zhang W, Brandson EK, Strathdee
SA, Montaner JSG, Hogg RS: Mortality is influenced by locality in a major
HIV/AIDS epidemic. HIV Med 2009, 10:274–281.
36. Lohse N, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Nielsen
L, Sorensen HT, Obel N: Comorbidity acquired before HIV diagnosis and
mortality in persons infected and uninfected with HIV: a Danish
population-based cohort study. JAIDS 2011, 57:334–339.
37. Waters L, Sabin CA: Late HIV presentation: epidemiology, clinical
implications and management. Expert Rev Anti Infect Ther 2011, 9:877–889.
38. Chadborn TR, Baster K, Delpech VC, Sabin CA, Sinka K, Rice BD, Evans BG:
No time to wait: how many HIV-infected homosexual men are
diagnosed late and consequently die? (England and Wales, 1993–2002).
AIDS 2005, 19:513–520.
39. Grangeiro A, Escuder MM, Menezes PR, Alencar R, de Castilho EA: Late entry
into HIV care: estimated impact on AIDS mortality rates in Brazil,
2003–2006. PLoS ONE 2011, 6:e14585.
40. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG: The late diagnosis
and consequent short-term mortality of HIV-infected heterosexuals
(England and Wales, 2000–2004). AIDS 2006, 20:2371–2379.
41. van Sighem A, Gras L, Reiss P, Brinkman K, de Wolf F: Life expectancy of
recently diagnosed asymptomatic HIV-infected patients approaches that
of uninfected individuals. AIDS 2010, 24:1527–1535.
Sabin BMC Medicine Page 7 of 72013, 11:251
http://www.biomedcentral.com/1741-7015/11/25142. Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M,
Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M,
Kaye S, Gabriel M, Phillips R, Weber J, Babiker A: Short-course antiretroviral
therapy in primary HIV infection. N Engl J Med 2013, 368:207–217.
43. Office for National Statistics: Statistics Bulletin: Life expectancy at birth and at




44. Lewden C, Gabillard D, Minga A, Ekouevi DK, Avit D, Konate I, Amani-Bosse
C, Messou E, Coffie P, Ouedraogo A, Laurent C, Anglaret X: CD4-specific
mortality rates among HIV-infected adults with high CD4 counts and no
antiretroviral treatment in West Africa. J Acquir Imm Defic Syndr 2012,
59:213–219.
45. Verguet S, Lim SS, Murray CJL, Gakidou E, Salomon JA: Incorporating loss
to follow-u p in estimates of survival among HIV-infected individuals in
sub-Saharan Africa enrolled in antiretroviral therapy programs. J Infect
Dis 2013, 207:72–79.
46. May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B,
Thiebaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P,
Lampe F, Ingle S, Guest JL, Crane HM, d’Arminio Monforte A, Vehreschild JJ,
Sterne JAC: Heterogeneity in outcomes of treated HIV-positive patients in
Europe and North America: relation with patient and cohort characteristics.
Int J Epidemiol 2012, 41:1807–1820.
Cite this article as: Sabin: Do people with HIV infection have a normal
life expectancy in the era of combination antiretroviral therapy? BMC
Medicine
10.1186/1741-7015-11-251
2013, 11:251Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
